For much of the company’s 141-year history, Japan’s Shionogi & Co. Ltd. has played safe when selling drugs in the United States and other overseas markets – relying on bigger partners to promote products and avoiding the cost of maintaining a large sales force.
Novartis won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the United States, at least until a patent dispute is resolved.
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.
Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.
The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.
British drugmaker Vectura Group Plc won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and was awarded $89.7 million in damages for the period from August 2016 through December 2018.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
The U.S. Supreme Court cast aside pharmaceutical company Allergan Plc’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe.